Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Vici, Patrizia ^a   Sergi, Domenico ^a   Pizzuti, Laura ^a   Mariani, Luciano ^a   Arena, Maria Grazia ^b   Barba, Maddalena ^a   Maugeri Saccà, Marcello ^a   Vincenzoni, Cristina ^a   Vizza, Enrico ^a   Corrado, Giacomo ^a   Paoletti, Giancarlo ^a   Tomao, Federica ^c   Tomao, Silverio ^c   Giannarelli, Diana ^a   Di Lauro, Luigi ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Toraldo Hospital   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Combination therapy; Gemcitabine; Ovarian cancer; Oxaliplatinum; Platinum resistant

Indexed keywords

GEMCITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONJUNCTIVITIS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROCEDURES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; SALVAGE THERAPY;

EID: 84881133586     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-49     Document Type: Article

References (50)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2013 63 11 30 10.3322/caac.21166 23335087
2. Therapeutic strategies in epithelial ovarian cancer. Kim A, Ueda Y, Naka T, Enomoto T, J Exp Clin Cancer Res 2012 31 14 10.1186/1756-9966-31-14 22330607
3. Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer. Bruchim I, Jarchowsky-Dolberg O, Fishman A, Eur J Obstet Gynecol Reprod Biol 2013 166 94 98 10.1016/j.ejogrb.2012.10.003 23088893
4. Optimal chemotherapy treatment in women with recurrent ovarian cancer. BisFung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P, Curr Oncol 2007 14 195 208 10.3747/co.2007.148 17938703
5. Role of gemcitabine in ovarian cancer treatment. Lorusso D, Di Stefano A, Fanfani F, Scambia G, Ann Oncol 2006 17 Suppl 5 v194 16807454
6. Oxaliplatin: mechanism of action and antineoplastic activity. Raymond E, Faivre S, Woynarowski JM, Chaney SG, Semin Oncol 1998 25 4 12 9865685 (Pubitemid 28248696)
7. Loss of DNA mismatch repair in acquired resistance to cisplatin. Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB, Cancer Res 1996 56 3087 3090 8674066 (Pubitemid 26199755)
8. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaïne MA, Tabah-Fisch I, Pouillart P, Ann Oncol 2002 13 258 266 10.1093/annonc/mdf018 11886003 (Pubitemid 34704978)
9. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. Piccart MJ, Green JA, Lacave AJ, Reed N, Vergote I, Benedetti-Panici P, Bonetti A, Kristeller-Tome V, Fernandez CM, Curran D, Van Glabbeke M, Lacombe D, Pinel MC, Pecorelli S, J Clin Oncol 2000 18 1193 1202 10715288 (Pubitemid 30159836)
10. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Chollet P, Bensmaïne MA, Brienza S, Deloche C, Curé H, Caillet H, Cvitkovic E, Ann Oncol 1996 7 1065 1070 10.1093/oxfordjournals.annonc.a010500 9037366 (Pubitemid 27050831)
11. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. Fracasso PM, Blessing JA, Morgan MA, Sood AK, Hoffman JS, J Clin Oncol 2003 21 2856 2859 10.1200/JCO.2003.03.077 12885801 (Pubitemid 46621833)
12. Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E, Cancer Chemother Pharmacol 1999 44 117 123 10.1007/s002800050955 10412945 (Pubitemid 29297057)
13. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M, Georgoulias V, Ann Oncol 2003 14 304 312 10.1093/annonc/mdg063 12562660 (Pubitemid 36305445)
14. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Raspagliesi F, Zanaboni F, Vecchione F, Hanozet F, Scollo P, Ditto A, Grijuela B, Fontanelli R, Solima E, Spatti G, Scibilia G, Kusamura S, Oncology 2004 67 376 381 10.1159/000082921 15713993
15. Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience. Germano D, Rosati G, Manzione L, J Chemother 2007 19 577 581 18073158 (Pubitemid 350177969)
16. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Ray-Coquard I, Weber B, Cretin J, Haddad-Guichard Z, Lévy E, Hardy-Bessard AC, Gouttebel MC, Geay JF, Aleba A, Orfeuvre H, Agostini C, Provencal J, Ferrero JM, Fric D, Dohollou N, Paraiso D, Salvat J, Pujade-Lauraine E, GINECO group, Br J Cancer 2009 100 601 607 10.1038/sj.bjc.6604878 19190632
17. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Kalykaki A, Papakotoulas P, Tsousis S, Boukovinas I, Kalbakis K, Vamvakas L, Kotsakis A, Vardakis N, Papadopoulou P, Georgoulias V, Mavroudis D, Hellenic Oncology Research Group, Anticancer Res 2008 28 495 500 18383891 (Pubitemid 351362859)
18. Clinical trials in recurrent ovarian cancer. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC, Gynecologic Cancer InterGroup, Int J Gynecol Cancer 2011 21 771 775 10.1097/IGC. 0b013e31821bb8aa 21543939
19. Optimal two-stage designs for phase II clinical trials. Simon R, Control Clin Trials 1989 10 1 10 10.1016/0197-2456(89)90015-9 2702835 (Pubitemid 19099520)
20. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhommé C, Ruffié P, Kayitalire L, Armand JP, Raymond E, Ann Oncol 2002 13 1479 1489 10.1093/annonc/mdf219 12196375
21. Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First study. Steer CB, Chrystal K, Cheong KA, Galani E, Marx GM, Strickland AH, Yip D, Lofts F, Gallagher C, Thomas H, Harper PG, Gynecol Oncol 2006 103 439 445 10.1016/j.ygyno.2006.03.017 16643993 (Pubitemid 44602149)
22. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Harnett P, Buck M, Beale P, Goldrick A, Allan S, Fitzharris B, De Souza P, Links M, Kalimi G, Davies T, Stuart-Harris R, Int J Gynecol Cancer 2007 17 359 366 10.1111/j.1525-1438.2007.00763.x 17362313 (Pubitemid 46426756)
23. Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer. Garcia AA, O'Meara A, Bahador A, Facio G, Jeffers S, Kim DY, Roman L, Gynecol Oncol 2004 93 493 498 10.1016/j.ygyno.2004. 02.007 15099968 (Pubitemid 38507624)
24. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. Joly F, Petit T, Pautier P, Guardiola E, Mayer F, Chevalier-Place A, Delva R, Sevin E, Henry-Amar M, Bourgeois H, Gynecol Oncol 2009 115 382 388 10.1016/j.ygyno.2009.08.024 19773043
25. Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer. Garcia AA, Yessaian A, Pham H, Facio G, Muderspach L, Roman L, Cancer Invest 2012 30 295 299 10.3109/07357907.2012.657812 22468744
26. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. Tas F, Guney N, Derin D, Aydiner A, Topuz E, Int J Clin Oncol 2008 13 156 160 10.1007/s10147-007-0740-4 18463961 (Pubitemid 351668175)
27. A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin. Mirza MR, Lund B, Lindegaard JC, Keldsen N, Mellemgaard A, Christensen RD, Bertelsen K, Gynecol Oncol 2010 119 26 31 10.1016/j.ygyno.2010.06.022 20638711
28. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study. Crespo G, Sierra M, Losa R, Berros JP, Villanueva N, Fra J, Fonseca PJ, Luque M, Fernández Y, Blay P, Sanmamed M, Muriel C, Esteban E, Lacave AJ, Int J Gynecol Cancer 2011 21 478 485 10.1097/IGC. 0b013e31820d738c 21436695
29. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Skarlos DV, Kalofonos HP, Fountzilas G, Dimopoulos MA, Pavlidis N, Razis E, Economopoulos T, Pectasides D, Gogas H, Kosmidis P, Bafaloukos D, Klouvas G, Kyratzis G, Aravantinos G, Anticancer Res 2005 25 3103 3108 16080573 (Pubitemid 41044707)
30. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer. Karaoglu A, Arslan UY, Ozkan M, Kalender ME, Alici S, Coskun U, Gumus M, Celenkoglu G, Er O, Sevinc A, Buyukberber S, Alkis N, Benekli M, Anatolian Society of Medical Oncology, Asian Pac J Cancer Prev 2009 10 63 66 20553084
31. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Petru E, Angleitner-Boubenizek L, Reinthaller A, Deibl M, Zeimet AG, Volgger B, Stempfl A, Marth C, Gynecol Oncol 2006 102 226 229 10.1016/j.ygyno.2005.12.017 16443259 (Pubitemid 44063577)
32. Overcoming platinum resistance in ovarian carcinoma. Matsuo K, Lin YG, Roman LD, Sood AK, Expert Opin Investig Drugs 2010 19 1339 1354 10.1517/13543784.2010.515585 20815774
33. The changing landscape of therapeutic strategies for recurrent ovarian cancer. Baumann KH, Wagner U, du Bois A, Future Oncol 2012 8 1135 1147 10.2217/fon.12.112 23030488
34. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Hochster H, Chen TT, Lu JM, Hills D, Sorich J, Escalon J, Ivy P, Liebes L, Muggia F, Gynecol Oncol 2008 108 500 504 10.1016/j.ygyno.2007.11.017 18191187
35. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma. Elkas JC, Winter WE 3rd, Chernofsky MR, Sunde J, Bidus MA, Bernstein S, Rose GS, Gynecol Oncol 2007 104 422 427 10.1016/j.ygyno.2006.08.011 16996118 (Pubitemid 46135647)
36. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Nicoletto MO, Falci C, Pianalto D, Artioli G, Azzoni P, De Masi G, Ferrazzi E, Perin A, Donach M, Zoli W, Gynecol Oncol 2006 100 318 323 10.1016/j.ygyno.2005.08.020 16239023 (Pubitemid 43075263)
37. Biweekly pegylated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: a Phase II study. Salah-Eldin MA, Wahba HA, Halim AA, Indian J Cancer 2012 49 169 175 10.4103/0019-509X.98944 22842184
38. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM, Bensmaïne MA, Itzhaki M, Marty M, Extra JM, Ann Oncol 1999 10 1125 1128 10.1023/A:1008334215414 10572615 (Pubitemid 29482472)
39. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Pectasides D, Pectasides M, Farmakis D, Gaglia A, Koumarianou A, Nikolaou M, Koumpou M, Kountourakis P, Papaxoinis G, Mitrou P, Economopoulos T, Raptis SA, Gynecol Oncol 2004 95 165 172 10.1016/j.ygyno.2004.06.029 15385127 (Pubitemid 39286293)
40. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Rosa DD, Awada A, Mano MS, Selleslags J, Lebrun F, Gil T, Piccart MJ, D'Hondt V, Arch Gynecol Obstet 2008 278 457 462 10.1007/s00404-008-0592-9 18273626
41. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Polyzos A, Kosmas C, Toufexi H, Malamos N, Lagadas A, Kosmidis C, Ginopoulos P, Ziras N, Kandilis K, Georgoulias V, Anticancer Res 2005 25 3559 3564 16101180 (Pubitemid 41105241)
42. Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330). Tsubamoto H, Kawaguchi R, Ito K, Shiozaki T, Takeuchi S, Itani Y, Arakawa A, Tabata T, Toyoda S, Anticancer Res 2013 33 1073 1079 23482784
43. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer. Levitt NC, Propper DJ, Madhusudan S, Braybrooke JP, Echeta C, Te Poele R, Davies SL, Flanagan E, Hickson ID, Joel S, Ganesan TS, Br J Cancer 2005 93 60 69 10.1038/sj.bjc.6602657 15956976 (Pubitemid 41076254)
44. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A, Reina S, Pirletti E, Gynecol Oncol 1999 72 60 64 10.1006/gyno.1998.5237 9889031 (Pubitemid 29045448)
45. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group. Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C, Br J Cancer 2004 90 2112 2117 15150623 (Pubitemid 38877624)
46. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, Stauch M, Paulenz A, Camara O, Keil E, Lichtenegger W, J Clin Oncol 2008 26 3176 3182 10.1200/JCO.2007.15.1258 18591555
47. A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote IB, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag DT, Ray-Coquard I, AURELIA Investigators AURELIA, J Clin Oncol 2012 30 Suppl BA5002
48. Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases. Ikeda Y, Takano M, Oda K, Kouta H, Goto T, Kudoh K, Sasaki N, Kita T, Kikuchi Y, Int J Gynecol Cancer 2013 23 355 360 10.1097/IGC.0b013e31827de69e 23358182
49. Clinical trials and future potential of targeted therapy for ovarian cancer. Itamochi H, Kigawa J, Int J Clin Oncol 2012 17 430 440 10.1007/s10147-012-0459-8 22926640
50. Platinum resistance in breast and ovarian cancer cell lines. Eckstein N, J Exp Clin Cancer Res 2011 30 91 10.1186/1756-9966-30-91 21967738